APP and Alzheimer disease: Using amyloid precursor protein (APP) transgenic mice, we surprisingly found that chronic intraperitoneal (i.p.)injection of AD animals with both amylin and its analog, pramlintide, reduces the amyloid burden as well as lowers the concentrations of Aβ (Figure 1) (Zhu et al., 2014).